Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Survodutide

A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)

Boehringer Ingelheim · Phase 3 · Completed · Enrollment 5530

NCT06077864

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

No selected arm reports a responder percent.

Show as table
Arm≥5%≥10%≥15%≥20%
survodutide 3.6 mgn/rn/rn/rn/r
survodutide 6.0 mgn/rn/rn/rn/r
Placebon/rn/rn/rn/r

Not shown

  • survodutide 3.6 mg: endpoint not reported
  • survodutide 6.0 mg: endpoint not reported
  • Placebo: endpoint not reported